Ann: Supplemental information to management prese, page-17

re: Ann: Supplemental information to manageme... If good people were not being hurt, this mass hysteria would be totally laughable.

As many, myself included, have stated, this is the exact same course ALL immunotherapies have taken to get to market.

Did anyone expect Prima Biomed to rewrite the rules???

Check out the link below. For anyone invested in, or considering investing in PRR it is worth the read, and has some great links for further analysis.
Took me 2 minutes to find this on google...

http://jco.ascopubs.org/content/30/10/1030.full

Below is the opening paragraph so you get the gist:

"The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a corresponding increase in overall survival (OS), have led to approval of new drugs and/or changes in standard of care. This suggests a growing belief in the oncology community that delaying progression in metastatic disease is a worthy goal, even if OS is not improved. But is a new treatment that improves PFS really an advance for patients? Or is it only lowering the bar to declare active some of our much-heralded new molecular targeted therapies? We believe that as a community, this trend requires discussion and debate."